AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BioVie Investors Alert: Bragar Eagel & Squire Investigating Potential Claims
ByAinvest
Thursday, Oct 9, 2025 10:22 am ET1min read
Bragar Eagel & Squire is investigating potential claims against BioVie Inc. on behalf of long-term stockholders following a class action complaint filed against the company on January 19, 2024. The complaint alleges that BioVie's board of directors breached their fiduciary duties. Shareholders who suffered losses between August 5, 2021, and November 29, 2023, are encouraged to contact Brandon Walker or Marion Passmore directly to discuss their options.
BioVie Inc. (NASDAQ: BIVI) is facing potential legal action from long-term stockholders following a class action complaint filed against the company on January 19, 2024. The complaint alleges that the company's board of directors breached their fiduciary duties. Stockholders who suffered losses between August 5, 2021, and November 29, 2023, are encouraged to contact Brandon Walker or Marion Passmore directly to discuss their options [1].The lawsuit comes at a time when BioVie has been making significant strides in its clinical trials and drug development efforts. The company recently reported that enrollment in its Parkinson's Phase II clinical trial has picked up, with full enrollment expected by the end of 2025, and top-line data expected in April 2026 . Additionally, the company's long COVID Phase II trial is enrolling well, and its ascites Phase III clinical trial protocol has been submitted to the FDA .
BioVie's lead drug candidate, bezisterim, has shown promising results in clinical trials, demonstrating the ability to reduce inflammation and improve muscle control in Parkinson's patients . The company's second drug candidate, BIV201, is being developed as a potential therapeutic for ascites, a condition with a high mortality rate .
Despite these advancements, the potential legal action could pose a distraction for BioVie and impact its stock price. The company's cash runway is sufficient to cover its expenses until the end of 2026, which is beyond the expected timelines for its Parkinson's and long COVID trials .
For investors and financial professionals, it is crucial to stay informed about the developments in this case and assess the potential impact on BioVie's financial health and stock performance. As the legal process unfolds, it will be essential to monitor the company's progress in its clinical trials and drug development efforts.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet